Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amarillo Biosciences (AMAR)

Amarillo Biosciences (AMAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amarillo Biosciences 8880 RIO SAN DIEGO DRIVE SUITE 800 SAN DIEGO CA 92108 USA

www.amarbio.com P: 858-869-2986

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds twelve of Amarillo Biosciences' shares and has provided over million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Beh'et's disease, and opportunistic infections in patients who are HIV positive. In its twenty three year history, the company has invested nearly $thirty eight million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon.

Key Statistics

Overview:

Market Capitalization, $K 25,244
Shares Outstanding, K 42,066
Float, K 27,616
% Float 65.65%
% of Insider Shareholders 34.35%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 20 K
Annual Net Income, $ -1,450 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -530 K

Growth:

1-Year Return 172.52%
3-Year Return 118.22%
5-Year Return 106.93%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/11/21
Earnings Per Share ttm -0.03
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-19 on 12/17/14

AMAR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -574.29%
Profit Margin % -7,250.00%
Debt/Equity 0.00
Price/Sales 1,777.83
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -144.00
60-Month Beta -0.06
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar